185675-41-6

Upstream product

• 100-39-0 benzyl bromide 
• 15042-01-0 5,6-O-isopropylidene-L-ascorbic acid 
• 202588-71-4 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone 
• 2871-84-3 (R)-3,4-bis(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)furan-2(5H)-one 

Downstream Products

• 203863-51-8 5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone 
• 1146484-20-9 3,4-dibenzyloxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone 
• 203863-45-0 3,4-dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone 

Relevant academic research and scientific papers

ASCORBIC ACID-RELATED COMPOUND AND ANTI-PLANT-VIRUS AGENT

The present invention provides a compound represented by formula (1) (wherein each of X1 and X2 independently represents -OR1, -NR2R3 or -CR4R5R6 or the like, each of

5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor

The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.

Organoalane-mediated isomerization of ascorbic and isoascorbic acid derivatives

Derivatives of L-ascorbic acid 2a, 10a/11a and D-isoascorbic acid 2b, 10b/11b, when treated with triisobutylaluminium, partly epimerize to give the corresponding derivatives of L-isoascorbic acid ent-2b, ent-10b or D-ascorbic acid ent-2a, ent-10a, ent-11a, respectively. Complete removal of the protecting groups is effected by hydrogenolysis of the benzylidene acetals ent-10 and ent-11a. This reaction leads to D-ascorbic acid ent-1a or L-isoascorbic acid ent-1b, respectively. Furthermore, the four acetonides 2 were converted by ozonolysis, transesterification and finally catalytic hydrogenation to the threonic and erythronic acid ketals 9. Copyright (C) Elsevier Science Ltd.